English | 中文

Hudson product information:

Hudson Cata#: HB0036

Product Name: Cabozantinib

CAS#: 183133-96-2

Chemical Formula: C45H57NO14

Exact Mass: 835.37791

Molecular Weight: 835.93

Purity: 98%

Storage Info: N/A

Synonym: dimethoxydocetaxel, US brand name: Jevtana. Code names: RPR-116258A; XRP6258; TXD 258; axoid XRP6258


Structure Formula:

Structure Formula Not Available.

5mg / $65.00
10 mg / $110.00

Product Info::

Cabozantinib (Marketed under the tradename Cometriq, formerly known as XL184) is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was developed by Exelixis Inc. Cabozantinib was granted orphan-drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib was approved by the U.S. FDA in November 2012 for the treatment of medullary thyroid cancer[2] and it is currently undergoing clinical trials for the treatment of prostate, ovarian, brain, melanoma, breast, non-small cell lung, hepatocellular and kidney cancers. (source: http://en.wikipedia.org/wiki/Cabozantinib).

If you want to make an order, please contact 1 (732) 640-2533

or email wzhuang@hudsonbiopharma.com


References (Review papers):

1: Hart CD, De Boer RH. Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer. Onco Targets Ther. 2013;6:1-7. doi: 10.2147/OTT.S27671. Epub 2013 Jan 3. PubMed PMID: 23319867; PubMed Central PMCID: PMC3540909.

2: Vaishampayan U. Cabozantinib as a Novel Therapy for Renal Cell Carcinoma. Curr Oncol Rep. 2013 Jan 5. [Epub ahead of print] PubMed PMID: 23292795.